Oncology Drug News: AstraZeneca reported positive late-stage results for a pill combination of Tagrisso plus Orpathys in MET-driven EGFR-mutant lung cancer after Tagrisso resistance, showing longer progression-free outcomes versus standard chemotherapy, with no new safety signals. Clinical Trial Updates: Daiichi Sankyo and AstraZeneca also highlighted DESTINY-Lung04 Phase 3 data for Enhertu as first-line HER2-mutant NSCLC, with statistically significant, clinically meaningful progression-free survival improvement while overall survival remains under evaluation. Biosimilars Deal: Henlius Biotech signed with Sandoz for up to 10 biosimilars/drug substances, with early assets including a cetuximab biosimilar and products for cholesterol and autoimmune disease, and potential payments up to about $322m tied to milestones. AI for Health & Research: China’s AI push is expanding beyond infrastructure into regional, application-focused deployment, while researchers also unveiled a soybean-specific AI model “Fengshu 2.0” to support data-assisted breeding. Public Health & Safety: Reports from Chengdu say China is widening scrutiny of religious beliefs in hospitals and schools, with staff and students’ families asked to disclose affiliations. Health-Adjacent Tech in Daily Life: JD.com’s 24-hour unmanned robotic coffee shop in Beijing signals how AI and robotics are moving into everyday services.